{"protocolSection":{"identificationModule":{"nctId":"NCT02149875","orgStudyIdInfo":{"id":"605872"},"organization":{"fullName":"Shanghai 6th People's Hospital","class":"OTHER"},"briefTitle":"Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke","officialTitle":"A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study."},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-01"},"primaryCompletionDateStruct":{"date":"2010-05","type":"ACTUAL"},"completionDateStruct":{"date":"2010-05","type":"ACTUAL"},"studyFirstSubmitDate":"2014-05-16","studyFirstSubmitQcDate":"2014-05-23","studyFirstPostDateStruct":{"date":"2014-05-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-04-12","resultsFirstSubmitQcDate":"2016-04-12","resultsFirstPostDateStruct":{"date":"2016-05-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-08-08","lastUpdatePostDateStruct":{"date":"2020-08-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hao Chen","investigatorTitle":"Doctor","investigatorAffiliation":"Shanghai 6th People's Hospital"},"leadSponsor":{"name":"Shanghai 6th People's Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups."},"conditionsModule":{"conditions":["Acute Cerebral Stroke Within 12 Hours for the First Time"],"keywords":["Acute ischemic stroke","Dl-3-n-butylphthalide","Cerebrolysin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":84,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dl-3-n-butylphthalide","type":"EXPERIMENTAL","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days","interventionNames":["Drug: Dl-3-n-butylphthalide"]},{"label":"Cerebrolysin","type":"EXPERIMENTAL","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days","interventionNames":["Drug: Cerebrolysin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.","armGroupLabels":["Dl-3-n-butylphthalide"],"otherNames":["CSPC NBP Pharmaceutical Co., Ltd., Shijiazhuang, China"]},{"type":"DRUG","name":"Cerebrolysin","description":"Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.","armGroupLabels":["Cerebrolysin"],"otherNames":["Ever Pharma, Unterach am Attersee, Austria"]},{"type":"DRUG","name":"Placebo","description":"100 ml saline intravenous infusion once daily for 10 days.","armGroupLabels":["Placebo"],"otherNames":["Hebei Tiancheng Pharmaceutical Co., Ltd., Cangzhou, China"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale Score","description":"Scores range from 0 to 42, with higher scores indicating increasing severity","timeFrame":"At 11-day and 21-day after therapy"}],"secondaryOutcomes":[{"measure":"Barthel Index Score","description":"Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence","timeFrame":"At 11-day and 21-day after therapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Acute ischemic stroke within 12 hours for the first time before entry into the study\n* National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25\n\nExclusion Criteria:\n\n* with lacunar infarction\n* with cerebral hemorrhagic infarction\n* with epilepsy or epileptic persons\n* with history of neurological diseases\n* with myocardial infarction,\n* with renal and hepatic abnormalities\n* with metabolic diseases\n* with contraindications to antiplatelet treatments","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Lixia Xue, M.D., Ph.D.","affiliation":"Shanghai 6th People's Hospital","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Shanghai Sixth People's Hospital","city":"Shanghai","zip":"200233","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"references":[{"pmid":"27168844","type":"DERIVED","citation":"Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H. Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke. Exp Ther Med. 2016 May;11(5):2015-2020. doi: 10.3892/etm.2016.3139. Epub 2016 Mar 10."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"From January 2010 to May 2010, a randomized, double-blind trial was conducted, which involved patients with AIS in the Neurology Ward of Shanghai Jiao Tong University Affiliated Sixth People's Hospital (Shanghai, China).","groups":[{"id":"FG000","title":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days\n\n\"Dl-3-n-butylphthalide\", \"Cerebrolysin\" and \"Placebo\" separately"},{"id":"FG001","title":"Cerebrolysin","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days\n\n\"Dl-3-n-butylphthalide\", \"Cerebrolysin\" and \"Placebo\" separately"},{"id":"FG002","title":"Placebo","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days\n\n\"Dl-3-n-butylphthalide\", \"Cerebrolysin\" and \"Placebo\" separately"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days."},{"id":"BG001","title":"Cerebrolysin","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days."},{"id":"BG002","title":"Placebo","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"60"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.1","spread":"6.3"},{"groupId":"BG001","value":"66.5","spread":"8.1"},{"groupId":"BG002","value":"68.4","spread":"4.2"},{"groupId":"BG003","value":"67.3","spread":"6.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"32"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"28"}]}]}]},{"title":"Time until admission","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"hour","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5.4","spread":"3.0"},{"groupId":"BG001","value":"5.0","spread":"3.3"},{"groupId":"BG002","value":"4.8","spread":"3.7"},{"groupId":"BG003","value":"5.1","spread":"3.3"}]}]}]},{"title":"Time until treatment","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"hour","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.7","spread":"5.9"},{"groupId":"BG001","value":"7.6","spread":"3.6"},{"groupId":"BG002","value":"5.6","spread":"3.0"},{"groupId":"BG003","value":"7.0","spread":"4.2"}]}]}]},{"title":"Systolic blood pressure","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mmHg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"148.6","spread":"14.6"},{"groupId":"BG001","value":"150.7","spread":"13.7"},{"groupId":"BG002","value":"152.5","spread":"12.8"},{"groupId":"BG003","value":"150.6","spread":"13.7"}]}]}]},{"title":"Diastolic blood pressure","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mmHg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88.7","spread":"10.7"},{"groupId":"BG001","value":"85.1","spread":"13.6"},{"groupId":"BG002","value":"87.2","spread":"12.5"},{"groupId":"BG003","value":"87.0","spread":"12.3"}]}]}]},{"title":"National Institutes of Health Stroke Scale score","description":"The scores range from 0 to 42, with higher scores indicating increasing severity. A score of \\< 4 represented low-degree impairment, between 4 and 15 represented medium-degree impairment, and a score of \\> 15 represented severe-degree impairment.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.4","spread":"4.38"},{"groupId":"BG001","value":"10.6","spread":"4.74"},{"groupId":"BG002","value":"10.2","spread":"3.72"},{"groupId":"BG003","value":"11.1","spread":"4.28"}]}]}]},{"title":"Barthel Index score","description":"The scores range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19.75","spread":"6.38"},{"groupId":"BG001","value":"22.25","spread":"7.16"},{"groupId":"BG002","value":"22.00","spread":"6.96"},{"groupId":"BG003","value":"21.33","spread":"6.83"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"National Institutes of Health Stroke Scale Score","description":"Scores range from 0 to 42, with higher scores indicating increasing severity","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"At 11-day and 21-day after therapy","groups":[{"id":"OG000","title":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days."},{"id":"OG001","title":"Cerebrolysin","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days."},{"id":"OG002","title":"Placebo","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"classes":[{"title":"Day 11","categories":[{"measurements":[{"groupId":"OG000","value":"8.78","spread":"2.48"},{"groupId":"OG001","value":"7.80","spread":"5.81"},{"groupId":"OG002","value":"8.85","spread":"4.43"}]}]},{"title":"Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":"2.34"},{"groupId":"OG001","value":"5.90","spread":"3.96"},{"groupId":"OG002","value":"7.30","spread":"4.78"}]}]}]},{"type":"SECONDARY","title":"Barthel Index Score","description":"Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"At 11-day and 21-day after therapy","groups":[{"id":"OG000","title":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days."},{"id":"OG001","title":"Cerebrolysin","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days."},{"id":"OG002","title":"Placebo","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}]}],"classes":[{"title":"Day 11","categories":[{"measurements":[{"groupId":"OG000","value":"35.25","spread":"10.57"},{"groupId":"OG001","value":"36.00","spread":"10.81"},{"groupId":"OG002","value":"31.00","spread":"8.68"}]}]},{"title":"Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"54.00","spread":"14.01"},{"groupId":"OG001","value":"53.75","spread":"13.10"},{"groupId":"OG002","value":"43.75","spread":"15.50"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"21 days","description":"Systematic methods include a physical examination (including heart rate, blood pressure and oxygen concentration), laboratory tests (including urine test, complete blood count, occult blood test, renal function, liver function, electrolyte and blood-glucose), electrocardiogram, cranial CT or MRI and chest radiograph.","eventGroups":[{"id":"EG000","title":"Dl-3-n-butylphthalide","description":"Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.","seriousNumAffected":8,"seriousNumAtRisk":20,"otherNumAffected":16,"otherNumAtRisk":20},{"id":"EG001","title":"Cerebrolysin","description":"Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.","seriousNumAffected":7,"seriousNumAtRisk":20,"otherNumAffected":12,"otherNumAtRisk":20},{"id":"EG002","title":"Placebo","description":"Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.","seriousNumAffected":11,"seriousNumAtRisk":20,"otherNumAffected":12,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Coagulation disorder","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"TESS","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":20},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":20},{"groupId":"EG002","numEvents":8,"numAffected":5,"numAtRisk":20}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"TESS","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":20}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"TESS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Cerebral hemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"TESS","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20}]}],"otherEvents":[{"term":"Erythrema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"TESS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"TESS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":20},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":20},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":20}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"TESS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":20},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":20}]},{"term":"Nausea/vomiting","organSystem":"General disorders","sourceVocabulary":"TESS","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":20},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":20},{"groupId":"EG002","numEvents":6,"numAffected":2,"numAtRisk":20}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"TESS","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":20},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":20},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":20}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Foremost is the relatively small sample size, and only patients with moderate severity of stroke were enrolled, so the efficacy results of this study should be interpreted with caution."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Hao Chen","organization":"Shanghai Sixth People's Hospital","email":"chenhao_316@aliyun.com","phone":"02164369181","phoneExt":"8405"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"},{"id":"C000027125","term":"3-n-butylphthalide"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"browseLeaves":[{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M352286","name":"3-n-butylphthalide","asFound":"Neck Position","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"}]}},"hasResults":true}